Tempus Offering Hope to Cancer Patients
People like Eric Lefkvsky are extracting data to help solve the mystery of cancer. His startup called Tempus has just received a second round of funding by significant investors totaling $210M, which will allow him to continue to build the most extensive database of molecular data on the planet. Once Eric Lefkovsky assembled the millions of documents needed to help the more than 17 million cancer patients known to be present in the United States, Tempus can invite physicians to access this data. Tempus allows real time actionable information to be extracted and real-time decisions to be made for cancer patients thru physician care.
The latest funding allows Tempus to keep growing. Tempus already has over 400 employees and is increasing by 30 new employees per month. Eric Lefkovsky and Brad Keywell co-founded Tempus together two years ago. By using genomic sequencing and machine learning, Tempus can bring together key elements which allow physicians to better understand their patient’s cancer and offer real-time recommendations drawn from the living records of successful cancer treatments. Tempus is now building its molecular data library with millions of records expected to be available from multiple cancer treatment centers. The information gathered in its library will be available to physicians to help with real-time decisions made for their cancer patients.
Tempus Collaborates with Medical Centers
Presently Tempus is joining forces with successful cancer treatment centers around the world like Mayo Clinic, University of Chicago, University of Michigan and Northwestern University. According to the staff at Tempus nearly half of all medical centers in the United States are affiliated with Tempus.
Co-Founders Bring Precision Medicine to Cancer
Eric Lefkovsky and Eric Keywell hope to bring better treatments to 20 to 30 percent of patients facing the mystery of cancer. Tempus also has hopes of going beyond cancer to find solutions and treatments for other diseases thru offering medical precision technology to physicians and researchers.